Tumor Necrosis Factor Ligand Superfamily Member 13
"Tumor Necrosis Factor Ligand Superfamily Member 13" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of tumor necrosis factor superfamily found on MACROPHAGES; DENDRITIC CELLS and T-LYMPHOCYTES. It occurs as transmembrane protein that can be cleaved to release a secreted form that specifically binds to TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; and B CELL MATURATION ANTIGEN.
MeSH Number(s)
D12.644.276.374.750.656
D12.644.276.972.656
D12.776.467.374.750.656
D12.776.467.972.656
D23.529.374.750.656
D23.529.972.656
Concept/Terms
Tumor Necrosis Factor Ligand Superfamily Member 13- Tumor Necrosis Factor Ligand Superfamily Member 13
- APRIL Protein
- TNF- and APOL-Related Leukocyte Expressed Ligand 2 Protein
- TNF and APOL Related Leukocyte Expressed Ligand 2 Protein
- A Proliferation Inducing Ligand Protein
- TALL-2 Protein
- TALL 2 Protein
Below are MeSH descriptors whose meaning is more general than "Tumor Necrosis Factor Ligand Superfamily Member 13".
Below are MeSH descriptors whose meaning is more specific than "Tumor Necrosis Factor Ligand Superfamily Member 13".
This graph shows the total number of publications written about "Tumor Necrosis Factor Ligand Superfamily Member 13" by people in Harvard Catalyst Profiles by year, and whether "Tumor Necrosis Factor Ligand Superfamily Member 13" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 3 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 1 | 2 | 3 |
| 2009 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
Below are the most recent publications written about "Tumor Necrosis Factor Ligand Superfamily Member 13" by people in Profiles.
-
APRIL expression is upregulated in atopic dermatitis skin lesions and at sites of antigen driven allergic skin inflammation in mice. Clin Immunol. 2020 10; 219:108556.
-
Trimeric HIV-1 gp140 fused with APRIL, BAFF, and CD40L on the mucosal gp140-specific antibody responses in mice. Vaccine. 2020 02 24; 38(9):2149-2159.
-
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv. 2019 11 12; 3(21):3248-3260.
-
Factors of the bone marrow microniche that support human plasma cell survival and immunoglobulin secretion. Nat Commun. 2018 09 12; 9(1):3698.
-
APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia. 2019 02; 33(2):426-438.
-
Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study. Arthritis Rheumatol. 2018 02; 70(2):266-276.
-
CD138 mediates selection of mature plasma cells by regulating their survival. Blood. 2017 05 18; 129(20):2749-2759.
-
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016 06 23; 127(25):3225-36.
-
Increased Serum B Cell Activating Factor and a Proliferation-inducing Ligand Are Associated with Interstitial Lung Disease in Patients with Juvenile Dermatomyositis. J Rheumatol. 2015 Dec; 42(12):2412-8.
-
Regulatory T cells prevent inducible BALT formation by dampening neutrophilic inflammation. J Immunol. 2015 May 01; 194(9):4567-76.